Ralph D. Sanderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ralph D. Sanderson has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Vishnu C. Ramani
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
9 shared publicationsAnurag Purushothaman
6 shared publicationsYang Yang
¶Center for Metabolic Bone Disease, University of Alabama at Birmingham, Birmingham, Alabama 35294-2182
6 shared publicationsIsrael Vlodavsky
4 shared publicationsCamilla A. Thompson
Department of Pathology, University of Alabama, Birmingham, Alabama 35294, USA
3 shared publicationsJoseph P. Ritchie
Department of Pathology, Center for Metabolic Bone Disease, and Comprehensive Cancer Center, University of Alabama at Birmingham, Alabama 35294, USA
3 shared publications
Latest Publications
- Open Access
- 8 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (15)
Glycocalyx heparan sulfate cleavage promotes endothelial cell angiopoietin-2 expression by impairing shear stress–related AMPK/FoxO1 signaling
Angiopoietin-2 (Ang-2) is a key mediator of vascular disease during sepsis, and elevated plasma levels of Ang-2 are associated with organ injury scores and poor clinical outcomes. We have previously observed that biomarkers of endothelial glycocalyx (EG) damage correlate with plasma Ang-2 levels, suggesting a potential mechanistic linkage between EG injury and Ang-2 expression during states of systemic inflammation. However, the cell signaling mechanisms regulating Ang-2 expression following EG damage are unknown. In the current study, we determined the temporal associations between plasma heparan sulfate (HS) levels as a marker of EG erosion and plasma Ang-2 levels in children with sepsis and in mouse models of sepsis. Second, we evaluated the role of shear stress–mediated 5′-adenosine monophosphate–activated protein kinase (AMPK) signaling in Ang-2 expression following enzymatic HS cleavage from the surface of human primary lung microvascular endothelial cells (HLMVECs). We found that plasma HS levels peaked before plasma Ang-2 levels in children and mice with sepsis. Further, we discovered that impaired AMPK signaling contributed to increased Ang-2 expression following HS cleavage from flow-conditioned HLMVECs, establishing a paradigm by which Ang-2 may be upregulated during sepsis.
- 8 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (15)
Open AccessGlycocalyx heparan sulfate cleavage promotes endothelial cell angiopoietin-2 expression by impairing shear stress–related AMPK/FoxO1 signaling
Angiopoietin-2 (Ang-2) is a key mediator of vascular disease during sepsis, and elevated plasma levels of Ang-2 are associated with organ injury scores and poor clinical outcomes. We have previously observed that biomarkers of endothelial glycocalyx (EG) damage correlate with plasma Ang-2 levels, suggesting a potential mechanistic linkage between EG injury and Ang-2 expression during states of systemic inflammation. However, the cell signaling mechanisms regulating Ang-2 expression following EG damage are unknown. In the current study, we determined the temporal associations between plasma heparan sulfate (HS) levels as a marker of EG erosion and plasma Ang-2 levels in children with sepsis and in mouse models of sepsis. Second, we evaluated the role of shear stress–mediated 5′-adenosine monophosphate–activated protein kinase (AMPK) signaling in Ang-2 expression following enzymatic HS cleavage from the surface of human primary lung microvascular endothelial cells (HLMVECs). We found that plasma HS levels peaked before plasma Ang-2 levels in children and mice with sepsis. Further, we discovered that impaired AMPK signaling contributed to increased Ang-2 expression following HS cleavage from flow-conditioned HLMVECs, establishing a paradigm by which Ang-2 may be upregulated during sepsis.
- Open Access
- 1 September 2016
- Published by Elsevier in Matrix Biology
- Vol. 55, 22-34
Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype
- 1 September 2016
- Published by Elsevier in Matrix Biology
- Vol. 55, 22-34
Open AccessChemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype
- Open Access
- 1 January 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (4) , 1652-1663
Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions
- 1 January 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (4) , 1652-1663
Open AccessFibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions
- Open Access
- 27 November 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (2) , 1598-1607
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
- 27 November 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (2) , 1598-1607
Open AccessTargeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
- Open Access
- 1 January 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (2) , 941-949
Shed Syndecan-1 Translocates to the Nucleus of Cells Delivering Growth Factors and Inhibiting Histone Acetylation
- 1 January 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (2) , 941-949
Open AccessShed Syndecan-1 Translocates to the Nucleus of Cells Delivering Growth Factors and Inhibiting Histone Acetylation
- Open Access
- 1 April 2014
- Published by Elsevier in Matrix Biology
- Vol. 35, 56-59
Heparan sulfate in the nucleus and its control of cellular functions
- 1 April 2014
- Published by Elsevier in Matrix Biology
- Vol. 35, 56-59
Open AccessHeparan sulfate in the nucleus and its control of cellular functions
- Open Access
- 1 April 2014
- Published by Elsevier in Matrix Biology
- Vol. 35, 215-222
Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse
- 1 April 2014
- Published by Elsevier in Matrix Biology
- Vol. 35, 215-222
Open AccessChemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse
- Open Access
- 1 April 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (14) , 10093-10099
Heparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes
- 1 April 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (14) , 10093-10099
Open AccessHeparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes
- Open Access
- 4 February 2013
- Published by Wiley in The FEBS Journal
- Vol. 280 (10) , 2294-2306
The heparanase/syndecan‐1 axis in cancer: mechanisms and therapies
Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up‐regulation of growth factor expression and increased shedding of syndecan‐1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan‐1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan‐1 axis hold promise for blocking the aggressive behaviour of cancer.
- 4 February 2013
- Published by Wiley in The FEBS Journal
- Vol. 280 (10) , 2294-2306
Open AccessThe heparanase/syndecan‐1 axis in cancer: mechanisms and therapies
Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up‐regulation of growth factor expression and increased shedding of syndecan‐1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan‐1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan‐1 axis hold promise for blocking the aggressive behaviour of cancer.
- Open Access
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (49) , 41288-41296
Heparanase Enhances the Insulin Receptor Signaling Pathway to Activate Extracellular Signal-regulated Kinase in Multiple Myeloma
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (49) , 41288-41296
Open AccessHeparanase Enhances the Insulin Receptor Signaling Pathway to Activate Extracellular Signal-regulated Kinase in Multiple Myeloma